Literature DB >> 21838750

Partial agonists for α4β2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects.

Ying Chen1, Lisa M Broad, Keith G Phillips, Ruud Zwart.   

Abstract

BACKGROUND AND
PURPOSE: Partial agonists selective for α4β2 nicotinic ACh receptors have been developed for smoking cessation as they induce weak activation of native α4β2* receptors and inhibit effect of nicotine. However, it is unclear whether at brain functions there is an existence of receptor reserve that allows weak receptor activation to induce maximum physiological effects. We assessed the extent of α4β2 partial agonist-induced increase of firing rate in dopaminergic neurons and evaluated the influence of receptor reserve. EXPERIMENTAL APPROACH: The relative maximal effects and potencies of six nicotinic agonists were assessed on recombinant human α4β2 and α7 receptors expressed in mammalian cell lines by measuring calcium influx. Agonist-induced increase of the spontaneous firing rate of dopaminergic neurons was recorded using microelectrodes in the ventral tegmental area of rat brain slices. KEY
RESULTS: All α4β2 partial and full agonists increased the firing rate concentration-dependently. Their sensitivity to subtype-selective antagonists showed predominant activation of native α4β2* receptors. However, partial agonists with relative maximal effects as low as 33% on α4β2 receptors maximally increased the firing rate and induced additional depolarization block of firing, demonstrating that partial activation of receptors caused the maximum increase in firing rate in the presence of a receptor reserve. CONCLUSIONS AND IMPLICATIONS: Partial α4β2 agonists induced relatively enhanced effects on the firing rate of dopaminergic neurons, and the effect was mainly attributed to the existence of native α4β2* receptor reserve. The results have implications in the understanding of physiological effects and therapeutic efficacies of α4β2 partial agonists.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21838750      PMCID: PMC3312495          DOI: 10.1111/j.1476-5381.2011.01628.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  A modification of receptor theory.

Authors:  R P STEPHENSON
Journal:  Br J Pharmacol Chemother       Date:  1956-12

2.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

3.  TC-2559 excites dopaminergic neurones in the ventral tegmental area by stimulating alpha4beta2-like nicotinic acetylcholine receptors in anaesthetised rats.

Authors:  Yun Wang; John L Sherwood; Colin P Miles; Gary Whiffin; David Lodge
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

4.  Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors.

Authors:  U Maskos; B E Molles; S Pons; M Besson; B P Guiard; J-P Guilloux; A Evrard; P Cazala; A Cormier; M Mameli-Engvall; N Dufour; I Cloëz-Tayarani; A-P Bemelmans; J Mallet; A M Gardier; V David; P Faure; S Granon; J-P Changeux
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

5.  Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors.

Authors:  Monica Mameli-Engvall; Alexis Evrard; Stéphanie Pons; Uwe Maskos; Torgny H Svensson; Jean-Pierre Changeux; Philippe Faure
Journal:  Neuron       Date:  2006-06-15       Impact factor: 17.173

6.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

7.  The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons?

Authors:  Elyssa B Margolis; Hagar Lock; Gregory O Hjelmstad; Howard L Fields
Journal:  J Physiol       Date:  2006-09-07       Impact factor: 5.182

Review 8.  Cytisine for smoking cessation: a literature review and a meta-analysis.

Authors:  Jean-François Etter
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

9.  RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells.

Authors:  Stuart J Lansdell; Veronica J Gee; Patricia C Harkness; Anne I Doward; Elizabeth R Baker; Alasdair J Gibb; Neil S Millar
Journal:  Mol Pharmacol       Date:  2005-08-24       Impact factor: 4.436

10.  5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors.

Authors:  Ruud Zwart; Lisa M Broad; Qian Xi; Martin Lee; Mirko Moroni; Isabel Bermudez; Emanuele Sher
Journal:  Eur J Pharmacol       Date:  2006-04-05       Impact factor: 4.432

View more
  3 in total

1.  Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats.

Authors:  Christopher S Tallarida; Ronald J Tallarida; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2015-02-07       Impact factor: 4.492

Review 2.  The nicotinic acetylcholine receptor as a target for antidepressant drug development.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  ScientificWorldJournal       Date:  2012-04-24

3.  Nicotine regulates activity of lateral habenula neurons via presynaptic and postsynaptic mechanisms.

Authors:  Wanhong Zuo; Cheng Xiao; Ming Gao; F Woodward Hopf; Krešimir Krnjević; J Michael McIntosh; Rao Fu; Jie Wu; Alex Bekker; Jiang-Hong Ye
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.